Skip to content

Evaluation of blood perfusion size in non-cancerous liver tissue before TACE/TAE: A clinical study of postoperative hepatic dysfunction

Evaluation of blood perfusion size in non-cancerous liver tissue before TACE/TAE: A clinical study of postoperative hepatic dysfunction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500095237
Enrollment
Unknown
Registered
2025-01-03
Start date
2024-02-08
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cancer

Interventions

high PVC group:None
low PVC group:None

Sponsors

The second Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Clinically diagnosed with HCC according to the National Health Commission's "Norms for the Diagnosis and Treatment of Primary Liver Cancer" (2019 edition), or pathologically diagnosed with HCC through liver biopsy; 2.Liver function is classified as Chid-Pugh A or B grade; 3.The patient's physical status was scored 0-2 points according to The Eastern Cooperative Oncology Group (ECOG, Table 1); 4.HCC did not have extrahepatic metastasis; 5.There were more than 2 HCC combinations in the liver, or single HCC nodules in the liver were too large to undergo surgery; 6.The patient did not receive TACE treatment in the early stage, and then received TACE treatment alone;

Exclusion criteria

Exclusion criteria: 1.People allergic to iodide oil and iodohexyl alcohol; 2.Patients with other liver diseases and heart, brain and kidney diseases; 3.Combined with HIV, HCV, HDV infection; 4.Patients with malignant tumors of other organs at the same time; 5.alcohol or drug abuse; 6.Lesion accounted for more than 75% of the total liver volume; 7.Patients with main portal vein cancer thrombus.

Design outcomes

Primary

MeasureTime frame
kidney function;Imaging examination;

Secondary

MeasureTime frame
Liver cancer tumor markers;

Countries

China

Contacts

Public Contactchunjuanxia

The second Affiliated Hospital of Kunming Medical University

976106135@qq.com+86 158 8781 6879

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026